Unknown PHASE2 INTERVENTIONAL 1-arm NCT03647956

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors: a Single Arm Phase 2 Study

Sponsor: The University of Hong Kong

Conditions EGFR Activating Mutation NSCLC Stage IIIB NSCLC Stage IV

Interventions Atezolizumab Bevacizumab Carboplatin Pemetrexed

Updated 7 times since 2018 Last updated: Apr 16, 2019 Started: Oct 1, 2018 Primary completion: Dec 31, 2019 Completion: Apr 3, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on EGFR Activating Mutation and NSCLC Stage IIIB, this trial is ongoing. The trial is conducted by The University of Hong Kong and has accumulated 7 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE2
May 2019 — Jan 2021 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Nov 2018 — May 2019 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2018 — Nov 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The University of Hong Kong

Data source: The University of Hong Kong

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hong Kong, Hong Kong